Osteoarthritis Market Research Report – Global Forecast Till 2023

Description:

Osteoarthritis Market Research Report, By Type (Hip Osteoarthritis, Spinal Osteoarthritis) By Diagnosis (Imaging, Joint Fluid Analysis) By Treatment (Medication, Surgery, Therapy) By End Users (Hospitals, Medical Institutes) - Global Forecast till 2023

Market Scenario:

Osteoarthritis is the most common form of arthritis which causes pain, swelling, and reduced motion in the joints. Usually, osteoarthritis affected joints are inclusive of hands, knees, hips and spine. Osteoarthritis breaks the cartilage of the joints which is a slippery tissue covering the ends of bones in a joint. Geriatric population and over-weighted individuals are at higher risks of osteoarthritis. Growing geriatric population, rising prevalence of the osteoarthritis and increasing per capita healthcare expenditure will drive the market growth during the forecast period, from 2017-2023. In 2015, according to the National Institutes of Health, the American geriatric population is expected to nearly double from 48 million in 2015 to 88 million by 2050. Moreover, according to the Centers for Disease Control and Prevention about 78 million (26%) U.S. adults aged 18 years or more are estimated to have doctor diagnosed arthritis, by 2020. However, low per capita income in the developing countries and side effects of the treatment procedures will restrain the market growth during the forecast period.

The global osteoarthritis market is expected to grow at an approximate CAGR of 6.8% during the forecast period.

Intended Audience

- Pharmaceutical companies
- Biotechnological institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers

Figure 1:- Global osteoarthritis market share, by region
Segmentation

The global osteoarthritis market is segmented on the basis of type, diagnosis, treatment, and end users.

On the basis of type, the market is segmented into hip osteoarthritis, wrist osteoarthritis, spinal osteoarthritis, and others.

On the basis of diagnosis, the market is segmented into imaging, joint fluid analysis, and others. The imaging segment is further segmented into X-rays, magnetic resonance imaging (MRI), and others.

On the basis of treatment, the market is segmented into medication, surgery, therapy, and others. The medication segmented is further segmented into analgesics and non-steroidal anti-inflammatory drugs, and others. The analgesics sub segment, by medication, is further segmented into acetaminophen, duloxetine, and others. The non-steroidal anti-inflammatory drugs sub segment, by medication, is further segmented into aspirin, ibuprofen, naproxen sodium and naproxen, and others.

On the basis of end users, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Regional Analysis

America dominates the global osteoarthritis market owing to a well-developed healthcare sector and huge patient population for osteoarthritis. Apart from this, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. In 2015, according to the Centres for Disease Control and Prevention, in the U.S. the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion.

Europe is the second largest osteoarthritis market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, increasing healthcare expenditures, well-developed healthcare sector and government support for research & development are projected to drive the market growth during the forecasted period. Regionally, Europe is divided into Western Europe and Eastern Europe. Western Europe hold the major share of the regional market, which is majorly contributed by Germany, the U.K., and France. However, Eastern Europe is the fastest growing region due to the huge opportunities in the untapped market.

Asia Pacific is the fastest growing region in global the market due to the presence of a huge patient population, continuously developing economies like India and China, and presence of huge opportunity in the market. According to Indian Brand Equity Foundation in 2017, the Indian healthcare sector is one of the fastest growing industries and is expected to advance at a CAGR of 22.87% during the review period to reach USD 280 billion by 2020. Moreover, favourable government policies and increasing healthcare expenditures fuels the market growth within the region.

On the other hand, the Middle East & Africa holds the least share in the global osteoarthritis market due to presence of poor economy, especially, in African region. Majority of the market of this region is held by the Middle East due to the well-developed healthcare sector and huge healthcare expenditure by the presence of economies like Kuwait, Saudi Arabia, Dubai and Qatar.
Introduction

The key players for the global osteoarthritis market are Abbott (U.S.), Novartis AG (Europe), Pfizer Inc. (U.S.), Eli Lilly and Company (U.S.), ABIODGEN PHARMA S.p.A (Europe), Merck Sharp & Dohme Corp. (U.S.), TissueGene Inc. (U.S.), Ampio Pharmaceuticals Inc. (U.S.), Regeneron (U.S.), and others.

Contents:

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges

Sources: WHO, annual reports, press release, white paper, and company presentation
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis
5.1 Porter's Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Osteoarthritis Market, by Type
6.1 Introduction
6.2 Hip Osteoarthritis
Market Estimates & Forecast, 2017 – 2023
6.3 Wrist Osteoarthritis
Market Estimates & Forecast, 2017 – 2023
6.4 Spinal Osteoarthritis
Market Estimates & Forecast, 2017 – 2023
6.5 Others

Chapter 7. Global Osteoarthritis Market, by Diagnosis
7.1 Introduction
7.2 Imaging
Market Estimates & Forecast, 2017 – 2023
7.2.1 X-rays
7.2.2 Magnetic resonance imaging (MRI)
7.2.3 Others
7.3 Joint Fluid Analysis
7.4 Others

Chapter 8. Global Osteoarthritis Market, by Treatment
8.1 Introduction
8.2 Medication
Market Estimates & Forecast, 2017 – 2023
8.2.1 Analgesics
Market Estimates & Forecast, 2017 – 2023
8.2.1.1 Acetaminophen
8.2.1.2 Duloxetine
8.2.1.3 Others
8.2.2 Non-steroidal Anti-Inflammatory Drugs
Market Estimates & Forecast, 2017 – 2023
8.2.2.1 Aspirin
8.2.2.2 Ibuprofen
8.2.2.3 Naproxen sodium and naproxen
8.2.2.4 Others

8.3 Therapies
Chapter 9. Global Osteoarthritis Market, by End Users

9.1 Introduction
9.2 Hospitals & Clinics
9.3 Medical Institutes
9.4 Research Organization
9.5 Others

Chapter 10. Global Osteoarthritis Market, by Region

10.1 Introduction
10.2 America
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles

12.1 Abbott.
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 Key Developments
12.1.5 SWOT Analysis

12.2 Novartis AG
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis

12.3 Pfizer Inc.
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis

12.4 Eli Lilly and Company.
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis

12.5 ABIODGEN PHARMA S.p.A
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis

12.6 Merck Sharp & Dohme Corp.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis

12.7 TissueGene Inc.
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis

12.8 Ampio Pharmaceuticals Inc.
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Regeneron
12.9.1 Overview
12.9.2 Product Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Osteoarthritis Market

Chapter 14 Appendix

LIST OF TABLES
Table 1 Osteoarthritis Industry Synopsis, 2017 – 2023
Table 2 Global Osteoarthritis Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Global Osteoarthritis Market by Region, 2017 – 2023, (USD Million)
Table 4 Global Osteoarthritis Market by Type, 2017 – 2023, (USD Million)
Table 5 Global Osteoarthritis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 6 Global Osteoarthritis Market by Treatment, 2017 – 2023, (USD Million)
Table 7 Global Osteoarthritis Market by End Users, 2017 – 2023, (USD Million)
Table 8 North America Osteoarthritis Market by Type, 2017 – 2023, (USD Million)
Table 9 North America Osteoarthritis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 10 North America Osteoarthritis Market by Treatment, 2017 – 2023, (USD Million)
Table 11 North America Osteoarthritis Market by End Users, 2017 – 2023, (USD Million)
Table 12 U.S. Osteoarthritis Market by Type, 2017 – 2023, (USD Million)
Table 13 U.S. Osteoarthritis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 14 U.S. Osteoarthritis Market by Treatment, 2017 – 2023, (USD Million)
Table 15 U.S. Osteoarthritis Market by End Users, 2017 – 2023, (USD Million)
Table 16 Canada Osteoarthritis Market by Type, 2017 – 2023, (USD Million)
Table 17 Canada Osteoarthritis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 18 Canada Osteoarthritis Market by Treatment, 2017 – 2023, (USD Million)
Table 19 Canada Osteoarthritis Market by End Users, 2017 – 2023, (USD Million)
Table 20 South America Osteoarthritis Market by Type, 2017 – 2023, (USD Million)
Table 21 South America Osteoarthritis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 22 South America Osteoarthritis Market by Treatment, 2017 – 2023, (USD Million)
Table 23 South America Osteoarthritis Market by End Users, 2017 – 2023, (USD Million)
Table 24 Europe Osteoarthritis Market by Type, 2017 – 2023, (USD Million)
Table 25 Europe Osteoarthritis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 26 Europe Osteoarthritis Market by Treatment, 2017 – 2023, (USD Million)
Table 27 Europe Osteoarthritis Market by End Users, 2017 – 2023, (USD Million)
Table 28 Western Europe Osteoarthritis Market by Type, 2017 – 2023, (USD Million)
Table 29 Western Europe Osteoarthritis Market by Diagnosis, 2017 – 2023, (USD Million)
Table 30 Western Europe Osteoarthritis Market by Treatment, 2017 – 2023, (USD Million)
Table 31 Western Europe Osteoarthritis Market by End Users, 2017 – 2023, (USD Million)